» Articles » PMID: 34989923

Automated Assessment of Cancer Drug Efficacy On Breast Tumor Spheroids in Aggrewell™400 Plates Using Image Cytometry

Overview
Journal J Fluoresc
Specialties Biophysics
Chemistry
Date 2022 Jan 6
PMID 34989923
Citations 6
Authors
Affiliations
Soon will be listed here.
Abstract

Tumor spheroid models have proven useful in the study of cancer cell responses to chemotherapeutic compounds by more closely mimicking the 3-dimensional nature of tumors in situ. Their advantages are often offset, however, by protocols that are long, complicated, and expensive. Efforts continue for the development of high-throughput assays that combine the advantages of 3D models with the convenience and simplicity of traditional 2D monolayer methods. Herein, we describe the development of a breast cancer spheroid image cytometry assay using T47D cells in Aggrewell™400 spheroid plates. Using the Celigo automated imaging system, we developed a method to image and individually track thousands of spheroids within the Aggrewell™400 microwell plate over time. We demonstrate the use of calcein AM and propidium iodide staining to study the effects of known anti-cancer drugs Doxorubicin, Everolimus, Gemcitabine, Metformin, Paclitaxel and Tamoxifen. We use the image cytometry results to quantify the fluorescence of calcein AM and PI as well as spheroid size in a dose dependent manner for each of the drugs. We observe a dose-dependent reduction in spheroid size and find that it correlates well with the viability obtained from the CellTiter96 endpoint assay. The image cytometry method we demonstrate is a convenient and high-throughput drug-response assay for breast cancer spheroids under 400 μm in diameter, and may lay a foundation for investigating other three-dimensional spheroids, organoids, and tissue samples.

Citing Articles

Using Microfluidic Hepatic Spheroid Cultures to Assess Liver Toxicity of T-2 Mycotoxin.

Taroncher M, Gonzalez-Suarez A, Gwon K, Romero S, Reyes-Figueroa A, Rodriguez-Carrasco Y Cells. 2024; 13(11.

PMID: 38891032 PMC: 11172061. DOI: 10.3390/cells13110900.


Building consensus on the application of organoid-based drug sensitivity testing in cancer precision medicine and drug development.

Xiang D, He A, Zhou R, Wang Y, Xiao X, Gong T Theranostics. 2024; 14(8):3300-3316.

PMID: 38855182 PMC: 11155402. DOI: 10.7150/thno.96027.


Assessing the distribution of cancer stem cells in tumorspheres.

Fotinos J, Marks M, Barberis L, Vellon L Sci Rep. 2024; 14(1):11013.

PMID: 38745039 PMC: 11094167. DOI: 10.1038/s41598-024-61558-6.


Anaplastic thyroid cancer spheroids as preclinical models to test therapeutics.

Hu J, Liu K, Ghosh C, Khaket T, Shih H, Kebebew E J Exp Clin Cancer Res. 2024; 43(1):85.

PMID: 38500204 PMC: 10949686. DOI: 10.1186/s13046-024-03009-8.


Functional precision oncology using patient-derived assays: bridging genotype and phenotype.

van Renterghem A, van de Haar J, Voest E Nat Rev Clin Oncol. 2023; 20(5):305-317.

PMID: 36914745 DOI: 10.1038/s41571-023-00745-2.


References
1.
Selby M, Delosh R, Laudeman J, Ogle C, Reinhart R, Silvers T . 3D Models of the NCI60 Cell Lines for Screening Oncology Compounds. SLAS Discov. 2017; 22(5):473-483. DOI: 10.1177/2472555217697434. View

2.
Sant S, Johnston P . The production of 3D tumor spheroids for cancer drug discovery. Drug Discov Today Technol. 2017; 23:27-36. PMC: 5497458. DOI: 10.1016/j.ddtec.2017.03.002. View

3.
Riedl A, Schlederer M, Pudelko K, Stadler M, Walter S, Unterleuthner D . Comparison of cancer cells in 2D vs 3D culture reveals differences in AKT-mTOR-S6K signaling and drug responses. J Cell Sci. 2016; 130(1):203-218. DOI: 10.1242/jcs.188102. View

4.
Mirab F, Kang Y, Majd S . Preparation and characterization of size-controlled glioma spheroids using agarose hydrogel microwells. PLoS One. 2019; 14(1):e0211078. PMC: 6345430. DOI: 10.1371/journal.pone.0211078. View

5.
Mortensen A, Morin E, Brown C, Lane D, Nestor M . Enhancing the therapeutic effects of in vitro targeted radionuclide therapy of 3D multicellular tumor spheroids using the novel stapled MDM2/X-p53 antagonist PM2. EJNMMI Res. 2020; 10(1):38. PMC: 7163001. DOI: 10.1186/s13550-020-0613-7. View